Annwen Jones, Chief Executive at Target Ovarian Cancer, shared a post on LinkedIn:
“I am honored to announce the establishment of the Patient Advisory Board for the Lancet Ovarian Cancer Commission.
Convened under the auspices of The Lancet, and chaired by Professor Isabelle Ray-Coquard and Professor Kathleen Moore, this Commission has an ambitious and urgent mandate: to drive and embed transformational change for everyone impacted by ovarian cancer globally.
The establishment of our Patient Advisory Board marks a pivotal step in ensuring that this work is shaped and guided by those with lived experience.
At our first meeting today, patient advocates from diverse regions and backgrounds alongside global ovarian cancer advocacy organizations will come together with commissioners with one shared commitment – to challenge inequities, elevate patient-centred priorities, and ensure that emerging policy recommendations translate into meaningful improvements in prevention, diagnosis, treatment, and quality of life.
As a Lancet Commissioner and Chair of the Patient Advisory Board, I am really energized for the important and urgent work that lies ahead.
Ovarian cancer remains one of the most lethal gynecological cancers worldwide, with stark disparities in outcomes between and within countries. Transformational change requires more than scientific advancement alone. It demands:
- Embedding lived experience at every level of decision-making.
- Addressing systemic inequities in access to care.
- Advancing research that reflects real-world patient needs.
- Influencing policy to close global gaps in outcomes.
The Patient Advisory Board will work alongside a stellar group of commissioners to ensure that the Commission’s recommendations are not only evidence-based, but grounded in what truly matters to patients.
Together, we aim to help shape a future where where you live no longer determines whether you survive or live well with ovarian cancer.
With thanks to Professor Ray-Coquard, Professor Moore, Chloe Wilson The Lancet Group, and the commissioners, for their commitment to putting the voices of advocates at the heart of the Commission’s work.
Above all, thanks to members of our Patient Advisory Board incl our global ovarian cancer advocacy partners for giving of their time and expertise to this important mission, Kim Hulscher, ESGO ENGAGe, Robin Cohen, World Ovarian Cancer Coalition, Abhishek Shankar, IGCAN at International Gynecologic Cancer Society, Runcie C.W. Chidebe, Maria del Milagro Cunibertti, Nimkee Gupta, Jennifer Hollington, Miho Katagi, Iren Lau, Cynthia Olotch, Sarah Powell, Sbba Siddique, Dee Sparacio, Eva-Maria Strömsholm and Diya Banerjee Sur.
We are all very grateful to the Commission’s sponsors and to Sophie King for her excellent support of our work.
Thank you for joining us today: Prf Ranjit Manchanda, Prf Leigh Pearce, Prf Jonathan Ledermann, Prf Asima Mukhopadhyay, Prf Don S. Dizon, Prf Florence Joly, Dr Laura Venegas.”
Other articles about The Lancet on OncoDaily.